Refractoriness to platelet transfusion

Current Opinion in Hematology

Volumn 9, Issue 6, 2002, Pages 516-520

  Rebulla, Paolo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION REACTION; COST BENEFIT ANALYSIS; HEALTH ECONOMICS; HLA MATCHING; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNE RESPONSE; LENGTH OF STAY; PLATELET REFRACTORINESS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION; TREATMENT OUTCOME; ECONOMICS; HISTOCOMPATIBILITY TEST; LEUKEMIA; METHODOLOGY; TREATMENT FAILURE;

HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA; PLATELET TRANSFUSION; TREATMENT FAILURE;

EID: 0036838811     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200211000-00009     Document Type: Review

References (26)

1. Schiffer CA, Anderson KC, Bennett CL, et al.: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1519-1538.
2. Kaneda T, Ku K, Oku H, et al.: Refractoriness to platelet transfusion following double valve replacement in an ITP patient who had undergone splenectomy. J Card Surg 1999, 14:386-389.
3. Springer W, von Ruecker A, Dickerhoff R: Difficulties in determining prophylactic transfusion thresholds of platelets in leukemia patients. Blood 1998, 92:2183-2184.
4. Sauz C, Freire C, Alcorta I, et al.: Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 2001, 41:762-765.
5. Kiefel V, König C, Kroll H, et al.: Platelet alloantibodies in transfused patients. Transfusion 2001, 41:766-770.
6. Fujino H, Ohta K, Taniue A, et al.: Primary refractoriness to platelet transfusion caused by Nak antibody alone. Vox Sang 2001, 81:42-44.
7. Pappalardo PA, Secord AR, Quitevis P, et al.: Platelet transfusion refractoriness associated with HPA-1 a (P1(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001, 41:984-987.
8. Saito S, Ota S, Seshimo H, et al.: Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002, 42:302-308. This study is a careful documentation that matching of the HLA-C antigens is required in some alloimmunized refractory patients.
9. Toor AA, Choo SY, Little JA: Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant 2000, 26:315-320.
10. Brand A: Alloimmune platelet refractoriness: incidence declines, unsolved problems persist. Transfusion 2001, 41:724-726.
11. Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusion. N Engl J Med 1997, 337:1861-1869.
12. Yankee RA, Grumet FC, Rogentine GN: Platelet transfusion therapy: the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969, 281:1208-1211.
13. Murphy S, Varma M: Selecting platelets for transfusion of the alloimmunized patient: a review. Immunohematology 1998, 14:117-123.
14. Petz LD, Garratty G, Calhoun L, et al.: Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000, 40:1446-1456.
15. Porretti L, Marangoni F, Rebulla P, et al.: Frozen platelet plates for platelet antibody detection and crossmatch. Vox Sang 1994, 67:52-57.
16. Kiss JE, Salamon DJ, Wilson J, et al.: Suitability of liquid-stored donor platelets in platelet compatibility testing. Transfusion 1989, 29:405-410.
17. Rebulla P, Morelati F, Burlini A, et al.: A semi-automated platelet crossmatching system for the management of platelet refractoriness. Proceedings Of The 54TH Annual Meeting of the American Association of Blood Banks, San Antonio, Texas, October 13-17, 2001. Bethesda, MD: American Association of Blood Banks; 11S.
18. Rebulla P, Morelati F, Revelli N, et al.: Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on crossmatching locally available platelet products. Transfusion 2001, 41(Suppl):11 S.
19. Bolgiano DC, Larson EB, Slichter SJ: A model to determine required pool size for HLA-typed community donor apheresis programs. Transfusion 1989, 29:306-310.
20. Freedman J, Gafni A, Garvey MB, et al.: A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 1989, 29:201-207.
21. von dem Borne AE, Ouwehand WH, Kuijpers RW: Theoretic and practical aspects of platelet crossmatching. Transfus Med Rev 1990, 4:265-278.
22. Valeri CR, Cassidy G, Pivacek LE, et al.: Anemia-induced increase in the bleeding time: implications for the treatment of nonsurgical blood loss. Transfusion 2001, 41:977-983. This study expands previous investigations performed in the rabbit animal model for hemorrhage and introduces the concept that bleeding risk could be decreased in refractory patients by increasing their Hematocrits.
23. Weissinger F, Sandmaier BM, Maloney DG, et al.: Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001, 98:3584-3588.
24. Friedmann AM, Sengul H, Lehmann H, et al.: Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002, 16:34-45. This study casts doubt on the rationale of the current prophylactic approach used for platelet transfusion in most institutions worldwide.
25. Strauss RG: Economy of platelet transfusions from a hospital perspective: pricing predicates practice. Transfusion 2001, 41:1617-1624. One of the few studies in transfusion medicine addressing economic issues.
26. Meehan KR, Matias CO, Rathore SS, et al.: Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 2000, 64:251-256.